Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H16O6.2C21H27NO |
| Molecular Weight | 1007.2599 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CCCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3.OC(CCCN4CCCCC4)(C5=CC=CC=C5)C6=CC=CC=C6.OC(=O)C7=CC8=C(C=CC=C8)C(CC9=C%10C=CC=CC%10=CC(C(O)=O)=C9O)=C7O
InChI
InChIKey=VKPDUGDKKSRHPC-UHFFFAOYSA-N
InChI=1S/C23H16O6.2C21H27NO/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*1-2,4-7,11-14,23H,3,8-10,15-18H2
| Molecular Formula | C23H16O6 |
| Molecular Weight | 388.3695 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H27NO |
| Molecular Weight | 309.4452 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Diphenidol, a nonphenothiazinic antiemetic agent used primarily in patients with Meniere disease and labyrinthopathies to treat vomiting and vertigo, is considered to be a relatively safe drug. Since it was first approved in the United States in 1967, this drug has been widely used in Latin America and Asia and has contributed to sporadic suicidal and accidental poisonings in mainland China and Taiwan. The mechanism by which diphenidol exerts its antiemetic and antivertigo effects is not precisely known. It is thought to diminish vestibular stimulation and depress labyrinthine function and as an antimuscarinic agent. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Diphenidol has no significant sedative, tranquilizing, or antihistaminic action. It has a weak peripheral anticholinergic effect. Diphenidol is used to relieve or prevent nausea, vomiting, and dizziness caused by certain medical problems.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.drugbank.ca/drugs/DB01231 |
6.37 null [pKi] | ||
Target ID: CHEMBL211 Sources: https://www.drugbank.ca/drugs/DB01231 |
5.55 null [pKi] | ||
Target ID: CHEMBL245 Sources: https://www.drugbank.ca/drugs/DB01231 |
5.95 null [pKi] | ||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18395442 |
6.04 null [pKi] | ||
Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18395442 |
5.89 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VONTROL Approved UseINDICATIONS
VERTIGO—‘Vontrol’ is indicated in peripheral (labyrinthine) vertigo and associated nausea and vomiting, as seen in such conditions as: Meniere’s disease, middle- and inner-ear surgery (labyrinthitis).
NAUSEA AND VOMITING—‘Vontrol’ is indicated in the control of nausea and vomiting, as seen in such conditions as: postoperative states, malignant neoplasms and labyrinthine disturbances. Launch Date1967 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
157.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18506741/ |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPHENIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
445.57 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18506741/ |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPHENIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18506741/ |
25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
DIPHENIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 mg/kg single, intravenous Highest studied dose Dose: 15 mg/kg Route: intravenous Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
Disc. AE: Central nervous system disorder NOS... AEs leading to discontinuation/dose reduction: Central nervous system disorder NOS (14 patients) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Central nervous system disorder NOS | 14 patients Disc. AE |
15 mg/kg single, intravenous Highest studied dose Dose: 15 mg/kg Route: intravenous Route: single Dose: 15 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. | 2010-09-16 |
|
| (2-Methyl-phen-yl)(phen-yl)methanol. | 2010-07-31 |
|
| Diphenidol inhibited sodium currents and produced spinal anesthesia. | 2010-06 |
|
| Neuropharmacology of vestibular system disorders. | 2010-03 |
|
| Generation of gold nanostructures at the surface of platinum electrode by electrodeposition for ECL detection for CE. | 2010-03 |
|
| [Clinical analysis on the cervical vertigo after operation of middle ear]. | 2009-05 |
|
| Ultra-fast chromatographic micro-assay for quantification of diphenidol in plasma: application in an oral multi-dose switchability trial. | 2008-10 |
|
| Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. | 2008-05-01 |
|
| Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: a long-term follow-up and randomized controlled study. | 2008-05 |
|
| Synthesis and pharmacological profile of a series of 1-substituted-2-carbonyl derivatives of Diphenidol: novel M4 muscarinic receptor antagonists. | 2008-03 |
|
| Enzymatic preparation of cefaclor with immobilized penicillin acylase. | 2008 |
|
| A novel amperometric sensor for the detection of difenidol hydrochloride based on the modification of Ru(bpy)(3)(2+) on a glassy carbon electrode. | 2007-10-15 |
|
| Capillary electrophoresis with end-column electrochemiluminescence for the analysis of chloroquine phosphate and the study on its interaction with human serum albumin. | 2007-06-22 |
|
| Determination of difenidol hydrochloride by capillary electrophoresis with electrochemiluminescence detection. | 2006-02-02 |
|
| Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study. | 2005-09 |
|
| Development of an HPLC method for determination of diphenidol in plasma and its application in an oral multi-dose bioequivalence study in a healthy female Mexican population. | 2005-07-15 |
|
| Diphenidol has no actual broad antiemetic activity in dogs and ferrets. | 2004-11 |
|
| Synthesis and antagonistic activity at muscarinic receptor subtypes of some derivatives of diphenidol. | 2003-09 |
|
| Simultaneous determination of enantiomers of structurally related anticholinergic analogs in human serum by liquid chromatography-electrospray ionization mass spectrometry with on-line sample cleanup. | 2001-10-25 |
|
| Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats. | 1995-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cons/diphenidol.html
For oral dosage form (tablets):
Adults: 25 to 50 milligrams (mg) every four hours as needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22683869
In vitro binding assays demonstrated that difenidol at micromolar concentrations bound to the α(1A)-, α(1B)- and α(1D)-adrenoceptor subtypes. Difenidol inhibited the phenylephrine-induced increase in [Ca(2+)](i) in Chinese hamster ovary cells expressing human α(1A)-, α(1B)- or α(1D)-adrenoceptor subtypes with similar IC(50) values in the low micromolar range.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:20 GMT 2025
by
admin
on
Mon Mar 31 17:49:20 GMT 2025
|
| Record UNII |
32021T3D6N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20949220
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL936
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
300000055431
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
C76675
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
11954372
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
26363-46-2
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
32021T3D6N
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY | |||
|
C004858
Created by
admin on Mon Mar 31 17:49:20 GMT 2025 , Edited by admin on Mon Mar 31 17:49:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |